THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE Patent applications |
Patent application number | Title | Published |
20150361142 | VACCINE FOR PREVENTING PORCINE EDEMA DISEASE - A purpose is to provide a vaccine which can prevent porcine edema disease in farms where porcine edema disease is anticipated. Meeting this purpose is a vaccine that is a fusion protein in which Stx2eB and a polypeptide having a coiled-coil forming unit are joined or a multimer of the fusion protein, and by immunizing pigs with this vaccine, it is possible to induce potent neutralizing antibodies and to defend against the onset of porcine edema disease. | 12-17-2015 |
20150344529 | VACCINE FOR HPV INFECTION AND/OR HEPATITIS B COMPRISING HPV/HBS CHIMERIC PROTEIN AS ACTIVE INGREDIENT - A chimeric protein of HPV-L2 peptide and HBs protein wherein the HPV-L2 peptide is (1) a peptide consisting of the core sequence region of 20 amino acid residues, (2) a peptide inside the core sequence region comprising 6 amino acid residues Gly-Gly-Leu-Gly-Ile-Gly or (3) a peptide consisting of 70 or less amino acid residues obtained by adding an amino acid sequence derived from HPV L2 protein at the N-terminal and/or the C-terminal of the core sequence region; and a vaccine for HPV infection and/or hepatitis B comprising the chimeric protein as an active ingredient. A vaccine comprising the chimeric protein of the present invention is the one that has an increased expression level in a host, an enhanced immune ability (early antibody induction) and a broader spectrum effective for a number of HPV types. | 12-03-2015 |
20150313731 | ARTIFICIAL BLOOD VESSEL USING DECELLULARIZED BLOOD VESSEL SHEET - An artificial blood vessel that can be transplanted to blood vessels with a small diameter, can be adjusted to an arbitrary size of a diameter, improves in invasiveness when a graft is taken, and overcomes the problem on the provision of a graft is provided. An artificial blood vessel prepared from a decellularized tubular structure, which is prepared by processing a decellularized, sheet-like blood vessel (decellularized blood vessel sheet) into a roll structure, and a tissue adhesive, wherein a portion which is contacted with blood that flows within the artificial blood vessel consists of the tissue of the tunica intima lined with the tissue of the tunica media whereas a portion of the sheet that overlaps when the sheet is processed into a roll structure (overlap width) consists of the tissue of the tunica media and wherein a tissue adhesive is applied to the overlap width. | 11-05-2015 |
20150151020 | FORMED SHEET PRODUCT AND HEMOSTATIC MATERIAL - A formed sheet product of a polymer composition comprising at least one protein selected from the group consisting of fibrinogen and thrombin and at least one polymer selected from the group consisting of an aliphatic polyester and a water-soluble polymer, and a laminated formed sheet product comprising a first polymer composition layer composed of fibrinogen and a water-soluble polymer and a second polymer composition layer composed of thrombin and an aliphatic polyester are provided. These formed products are applied onto a wound site and function as a hemostatic material. | 06-04-2015 |
20150132279 | RADIATION STERILIZATION-RESISTANT PROTEIN COMPOSITION - A protein composition which comprises a mixture of glycine, phenylalanine and histidine and/or a cellulose ether derivative as an additive and has resistance to radiation sterilization. | 05-14-2015 |
20150125511 | STERILE COMPOSITION - A sterile composition which comprises a protein and an aliphatic polyester containing the protein and is sterilized with radiation. In this sterile composition, the structure and function (activity) of the protein are retained. | 05-07-2015 |
20150086590 | LPS VACCINE - A vaccine composition for birds comprising as an active ingredient a structure containing O-antigen derived from Gram-negative bacteria, provided that said structure does not contain a whole cell, and a process for preparing the same are provided. By using a structure containing O-antigen (e.g. lipopolysaccharide) derived from Gram-negative bacteria as an active ingredient in accordance with the present invention, alleviation of inoculation reaction and reduction in an amount of injection are attained as compared to the conventional whole-cells vaccine to thereby allow for the increase in the number of other antigens to be mixed therewith. | 03-26-2015 |
20150050716 | NOVEL ADAMTS-13 MUTANT - An enhanced disintegrin-like domain, and metalloprotease, with an isolated human thrombospondin type 1 motif, member 13 (ADAMTS-13) that includes substitutions at one or more positions in the isolated human ADAMTS-13. | 02-19-2015 |
20140343248 | METHOD FOR ENHANCING IMMUNE RESPONSE WITH PEPTIDE - An object of the present invention is to provide a safe and effective method for enhancing an immune response and a medicament for preventing or treating Alzheimer disease comprising amyloid β peptide that induces an enhanced immune response. An amyloid β peptide or a portion thereof with addition or insertion of cysteine and a method for enhancing an immune response using the peptide or a method for enhancing an immune response using the peptide together with an adjuvant. A medicament for preventing or treating Alzheimer disease comprising an amyloid β peptide or a portion thereof that induces an enhanced immune response. A DNA vaccine, that may have the same effect, comprising the gene encoding an amyloid β peptide or a portion thereof that induces an enhanced immune response with addition or insertion of cysteine. | 11-20-2014 |
20140193881 | NOVEL ADAMTS-13 MUTANT - An enhanced disintegrin-like domain, and metalloprotease, with an isolated human thrombospondin type 1 motif, member 13 (ADAMTS-13) that includes substitutions at one or more positions in the isolated human ADAMTS-13. | 07-10-2014 |
20140065179 | ADJUVANT COMPOSITION CONTAINING CITRULLINE - A novel adjuvant composition is provided that is excellent in safety and convenience as compared to the conventional adjuvant such as Alum. An adjuvant composition comprising citrullines, which are water soluble substance present in the living body, and/or a salt thereof; a vaccine composition comprising said adjuvant composition and an antigen; a process for preparing said adjuvant composition and said vaccine composition; and a method for administering said adjuvant composition and said vaccine composition are provided. | 03-06-2014 |
20140044743 | METHOD FOR ENHANCING IMMUNE RESPONSE WITH PEPTIDE - An object of the present invention is to provide a safe and effective method for enhancing an immune response and a medicament for preventing or treating Alzheimer disease comprising amyloid β peptide that induces an enhanced immune response. An amyloid β peptide or a portion thereof with addition or insertion of cysteine and a method for enhancing an immune response using the peptide or a method for enhancing an immune response using the peptide together with an adjuvant. A medicament for preventing or treating Alzheimer disease comprising an amyloid β peptide or a portion thereof that induces an enhanced immune response. A DNA vaccine, that may have the same effect, comprising the gene encoding an amyloid β peptide or a portion thereof that induces an enhanced immune response with addition or insertion of cysteine. | 02-13-2014 |
20130288338 | RECOMBINANT VACCINIA VIRUS HAVING HEMAGGLUTININ PROTEIN GENES DERIVED FROM NOVEL INFLUENZA VIRUSES - Provided are a highly-safe recombinant vaccinia virus that is effective in preventing the onset of symptoms due to infection by novel influenza viruses, and a vaccine for the novel influenza viruses containing the recombinant vaccinia virus. This recombinant vaccinia virus is capable of expressing the hemagglutinin protein genes of the novel influenza virus. This novel influenza vaccine contains the recombinant vaccinia virus. | 10-31-2013 |
20130253580 | ADHESIVE APPLICATOR FOR BIOLOGICAL TISSUE - An adhesive applicator for biological tissue ( | 09-26-2013 |
20130252902 | TYPE A2 BOTULINUM TOXIN PREPARATION - A method for treating a patient who has a neutralizing antibody to a type A1 botulinum toxin. The method includes administering 150 kDa type A neurotoxin from type A2 | 09-26-2013 |
20130183366 | SHEET PREPARATION FOR TISSUE ADHESION - A sheet preparation characterized by that fibrinogen is held on one surface of a sheet-shaped support and thrombin is held on the other surface of the sheet-shaped support where fibrinogen is not held and that fibrinogen and thrombin are held separately from each other, and a process for preparing the same. | 07-18-2013 |
20130183330 | RECOMBINANT AVIAN INFECTIOUS CORYZA VACCINE AND PROCESS FOR PREPARING SAME - A recombinant avian infectious coryza vaccine and a process for preparing the same are provided. A process for preparing a recombinant avian infectious coryza vaccine which comprises step of constructing | 07-18-2013 |
20120244184 | MODIFIED PEPTIDE VACCINE DERIVED FROM INFLUENZA M2 - A modified peptide derived from matrix protein 2 (hereinafter also referred to as “M2”), one of surface layer proteins of influenza virus, and a method for utilization of the modified peptide are provided. A peptide (hereinafter also referred to as “M2eC peptide”) that is made up by inserting cysteine residue(s) into a peptide (hereinafter also referred to as “M2e”) consisting of 23 amino acid residues of from positions No. 2 to No. 24 of M2 in influenza virus type A, a fusion protein consisting of said modified peptide and a polypeptide, an influenza vaccine comprising said modified peptide or said fusion protein as an active ingredient, a device which can be delivered into the body comprising said influenza vaccine, a nucleic acid fragment consisting of a nucleotide sequence encoding the amino acid sequence of said modified peptide or said fusion protein, an expression vector in which said nucleic acid fragment is incorporated, a host in which said expression vector is introduced, and an antibody that has a protective effect against influenza virus. | 09-27-2012 |
20120225818 | PLASMA PROTEIN EFFECTIVE FOR SUPPRESSING COUGH - The activated Factor XI is provided as an antitussive for cough caused by the stimulation at the tracheal bifurcation such as chronic cough. A pharmaceutical composition for prevention, treatment and/or symptom amelioration of cough, comprising a polypeptide chain as an active ingredient and a pharmaceutically acceptable carrier, wherein the polypeptide chain consists of a full length amino acid sequence constituting activated Factor XI (hereinafter also referred to as “FXIa”), the amino acid sequence with one or several amino acids therein being deleted, substituted or added, or a partial sequence of either of the above amino acid sequences, or an amino acid sequence comprising as a part any of the above amino acid sequences. | 09-06-2012 |
20120177718 | WOUND-COVERING MATERIAL - A new wound-covering material that protects and repairs a wound area caused by an operation, trauma, burn, and the like is provided. The present invention relates to a wound-covering material comprising thrombin, fibrinogen and a bioabsorbable supporting material. The wound-covering material may further be overlaid with a covering material for retaining moisture. The wound-covering material may be consisted of a kit of either (1) a bioabsorbable supporting material holding thrombin, and fibrinogen; or (2) a bioabsorbable supporting material holding thrombin, and a bioabsorbable supporting material holding fibrinogen; or (3) thrombin, fibrinogen and a bioabsorbable supporting material. Besides, each of the kits may be combined with a covering material for retaining moisture. | 07-12-2012 |
20120003257 | RECOMBINANT AVIAN INFECTIOUS CORYZA VACCINE AND PROCESS FOR PREPARING SAME - A recombinant avian infectious coryza vaccine and a process for preparing the same are provided. A process for preparing a recombinant avian infectious coryza vaccine which comprises step of constructing | 01-05-2012 |
20110275139 | RECOMBINANT VACCINIA VIRUS HAVING HEPATITIS C VIRUS GENE - Provided is a recombinant virus which is efficacious in preventing the onset of hepatitis C infection and has a high safety. Also provided is a vaccine for hepatitis C virus which contains the recombinant virus. A recombinant vaccinia virus which can express hepatitis C virus gene. The hepatitis C virus vaccine as described above contains the recombinant virus as described above. | 11-10-2011 |
20110268756 | MODIFIED AMYLOID BETA PEPTIDE - An object of the invention is to provide a peptide based on a sequence of an amyloid β peptide that may allow for induction of enhanced immune response and is safe and efficacious for prophylaxis and treatment of Alzheimer disease. An amyloid β peptide or a portion thereof with addition or insertion of cysteine or a cysteine analogue, and a method for enhancing immune response to amyloid β using said peptide, a medicament for prophylaxis and treatment of Alzheimer disease using said amyloid β peptide that induces an enhanced immune response, and a DNA vaccine comprising a gene coding for an amyloid β peptide or a sequence derived from an amyloid β peptide with addition or insertion of cysteine or a cysteine analogue, as expected to be similarly efficacious. | 11-03-2011 |
20110262998 | PROCESS FOR PREPARING INCLUSION BODY-FORMING PROTEIN - A process for preparing an inclusion body-forming protein is provided. A nucleic acid fragment consisting of a nucleotide sequence coding for a modified alkaline phosphatase signal peptide (modified APSP) where leucine at the 13th position in the amino acid sequence shown in SEQ ID NO: 1 is substituted with proline and/or alanine at the 21st position is substituted with the other amino acid, downstream of which nucleotide sequence is bound a nucleotide sequence of a gene of a protein of interest, and a process for preparing an inclusion body-forming protein consisting of the following steps: (1) preparing an expression vector in which a nucleic acid fragment is incorporated consisting of a nucleotide sequence coding for a modified signal peptide downstream of which is bound a nucleotide sequence of a gene of a protein of interest, (2) preparing a host cell transformed with the expression vector that produces an inclusion body-forming protein, and (3) purifying the inclusion body-forming protein from culture obtained by culturing the host cell that produces the inclusion body-forming protein. The above other amino acid is selected from the group consisting of aspartic acid, glutamic acid, lysine, histidine, phenylalanine and tyrosine. | 10-27-2011 |
20110196415 | MATERIAL FOR ANEURYSM CURING - It is an object of the present invention to provide a polymer material, the histocompatibility of which has been improved by irradiation of ion beam, which prevents an aneurysm having a risk of rupture from actually rupturing. The present invention provides a material for treating aneurysms, which is composed of a polymer material containing carbon as a constitutional element, and which is produced by modifying at least a portion of the surface thereof by ion bombardment. | 08-11-2011 |
20110081376 | METHOD FOR USING INACTIVATED JAPANESE ENCEPHALITIS VIRUS PARTICLES AS ADJUVANT - A method for using inactivated Japanese encephalitis virus particles as an adjuvant of a vaccine is provided. A method for using inactivated Japanese encephalitis virus (JEV) particles as an adjuvant of various vaccines or a mixed vaccine, said JEV particles being obtained by inoculating JEV Beijing-1 strain to Vero cells, culturing said JEV-infected cells to give cultured cells or culture supernatant, purifying JEV particles from said cultured cells or culture supernatant and inactivating said JEV particles with formalin, a method for preparing a (mixed) vaccine which comprises a step of letting inactivated Japanese encephalitis virus be contained, and a mixed vaccine prepared by said method. | 04-07-2011 |
20110038847 | PROCESS FOR PREPARING BIOABSORBABLE SHEET PREPARATION HOLDING THROMBIN - A process for preparing a bioabsorbable sheet preparation holding thrombin is provided. A process for preparing a bioabsorbable sheet preparation holding thrombin which comprises immersing a bioabsorbable sheet consisting of polyglycolic acid in a thrombin solution containing thrombin as an active ingredient, glycerol as a softening agent, Tween 80 as a permeating agent, and optionally histidine and trehalose as a stabilizing agent followed by drying to hold thrombin on said bioabsorbable sheet, and a bioabsorbable sheet preparation holding thrombin prepared by said process. | 02-17-2011 |
20110033431 | TYPE A2 BOTULINUM TOXIN PREPARATION - A pharmaceutical preparation for use in a patient who has a neutralizing antibody to a | 02-10-2011 |
20090214587 | Recombinant virus and use thereof - The present invention provides a recombinant virus which is efficacious and highly safe in preventing the onset of SARS infection and a vaccine for SARS coronavirus containing the same. The recombinant virus of the invention can express a SARS coronavirus gene. | 08-27-2009 |